Hong-Shiue Chou
Overview
Explore the profile of Hong-Shiue Chou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chan K, Lai Y, Hung H, Lee J, Cheng C, Wang Y, et al.
Cancers (Basel)
. 2025 Jan;
17(2.
PMID: 39857970
Background: Liver transplantation (LT) is a promising treatment option for patients with hepatocellular carcinoma (HCC) comorbid with cirrhosis. However, HCC with portal vein tumor thrombosis (PVTT) remains an absolute contraindication...
2.
Lai Y, Hung H, Lee J, Wang Y, Cheng C, Wu T, et al.
Ann Transplant
. 2024 Dec;
29:e945297.
PMID: 39623708
BACKGROUND Liver transplantation (LT) is the preferred treatment for patients with cirrhosis who have hepatopulmonary syndrome (HPS). However, the effect of HPS on LT remains controversial. We assessed the correlation...
3.
Shih H, Lai Y, Hung H, Lee J, Wang Y, Wu T, et al.
Dig Dis Sci
. 2024 Jun;
69(8):3069-3078.
PMID: 38824258
Background: In many Asian hepatocellular carcinoma (HCC) guidelines, resection is an option for multiple HCCs. It is difficult to compare small but multiple tumors vs. fewer large tumors in terms...
4.
Wang W, Wu T, Hung H, Lee J, Cheng C, Wang Y, et al.
Medicine (Baltimore)
. 2024 Apr;
103(14):e37632.
PMID: 38579088
Donor safety is crucial for living donor liver transplantation (LDLT), and sufficient liver regeneration significantly affects outcomes of living donors. This study aimed to investigate clinical factors associated with liver...
5.
Hung H, Lai Y, Lee J, Wang Y, Cheng C, Wu T, et al.
Hepatol Res
. 2024 Mar;
54(9):838-850.
PMID: 38451566
Aim: We aimed to investigate the prognostic factors for salvage liver transplant in patients with early hepatocellular carcinoma recurrence after hepatectomy. Methods: This retrospective analysis included 53 patients who underwent...
6.
Cheng C, Hung H, Lee J, Wang Y, Wu T, Lee C, et al.
Ann Transplant
. 2023 Apr;
28:e938731.
PMID: 37081752
BACKGROUND Taiwan has a high prevalence of hepatitis B virus (HBV) infection. HBV-related end-stage liver disease is the leading cause of liver transplantation (LT). Tenofovir alafenamide (TAF) is a recently...
7.
Lee W, Hung H, Lee J, Huang C, Huang P, Gu P, et al.
Viruses
. 2023 Mar;
15(3).
PMID: 36992386
Liver transplant recipients are immunocompromised and have low immunogenicity to produce antibodies in anti-COVID-19 vaccination. Whether immunosuppressant adjustment could facilitate anti-COVID-19 antibody production in anti-COVID-19 mRNA vaccination is undetermined. Our...
8.
Chan K, Lai Y, Hung H, Lee J, Cheng C, Wang Y, et al.
J Hepatocell Carcinoma
. 2023 Feb;
10:281-290.
PMID: 36845025
Background: Tyrosine kinase inhibitors (TKIs) remain the primary therapeutic option for patients with advanced-stage hepatocellular carcinoma (HCC). However, the selection of a suitable TKI is an issue in real-world clinical...
9.
Lee W, Wu T, Cheng C, Wang Y, Hung H, Lee J, et al.
Metabolites
. 2023 Jan;
13(1).
PMID: 36677042
Liver transplantation can be performed with deceased or living donor allografts. Deceased liver grafts are donated from brain- or circulation-death patients, and they have usually suffered from a certain degree...
10.
Cheng C, Hung H, Lee J, Huang P, Gu P, Lai Y, et al.
Vaccines (Basel)
. 2022 Nov;
10(11).
PMID: 36366336
Liver transplant recipients on chronic immunosuppression show an attenuated antibody response after SARS-CoV-2 vaccination. Adjusting immunosuppressants during vaccination remains debated. We enrolled 380 liver transplant recipients receiving 2 doses of...